Abstracts Archive - Page 783 of 1683 - ATC Abstracts

2018 American Transplant Congress
CD19+ Cell Ratio as a Predictive Marker of Antibody Mediated Rejection in ABO Incompatible Kidney Transplantation
K. Unagami,¹ R. Maenosono,² M. Furusawa,² Y. Kakuta,² M. Okumi,² H. Ishida,² K. Tanabe,² K. Nitta.¹
¹Nephrology, Tokyo Women's Medical University, Tokyo, Japan; ²Urology, Tokyo Women's Medical University, Tokyo, Japan.
Background: Rituximab has been suggested to deplete B cells and decrease the possibility of antibody mediated rejection (AMR) in ABO-incompatible living kidney transplantation (ABO-ILKT). We…
2018 American Transplant Congress
Title: Donor-Derived Cell Free DNA Predicts Development of Clinically Significant Changes in Donor Specific Antibody Following Kidney Transplant
A. Brubaker,¹ D. Stoltz,¹ M. Grskovic,² R. Woodward,² A. Gallo.¹
¹Department of Surgery, Division of Abdominal Transplantation, Stanford University, Stanford, CA; ²CareDx, Brisbane, CA.
Background: Recently, high immunologic risk patients comprise a significant percentage of the total adult renal transplants performed yearly. Surveillance management of these patients and interpretation…
2018 American Transplant Congress
Eculizumab for the Treatment of Antibody Mediated Rejection in Kidney Transplant Recipients: A Single Center Experience
A. Chi, J. Phillips, D. Quan.
Pharmaceutical Services, UCSF Medical Center, San Francisco, CA.
BACKGROUND: Antibody mediated rejection (ABMR) accounts for 20-30% of acute rejection episodes and can affect long-term renal allograft survival. The complement system plays an active…
2018 American Transplant Congress
Molecular Monitoring for Kidney Allograft Injury Following HLA Incompatible Transplantation
A. Jackson,¹ B. Iglehart,¹ S. Bagnasco,³ N. Desai.²
¹Medicine, Johns Hopkins University, Baltimore, MD; ²Surgery, Johns Hopkins University, Baltimore, MD; ³Pathology, Johns Hopkins University, Baltimore, MD.
Elevated donor derived cell free DNA (ddcfDNA) has been shown to correlate with allograft rejection following heart, lung, and kidney transplantation. We investigated whether sequential…
2018 American Transplant Congress
C1q-Binding Donor-Specific Anti-HLA Antibodies for Clinical Decision Making in Kidney Recipients with Antibody-Mediated Rejection Receiving Standard of Care Treatment
C. Lefaucheur,¹ D. Viglietti,¹ Y. Bouatou,¹ O. Aubert,¹ A. Zeevi,² A. Loupy.¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France; ²University of Pittsburgh Medical Center, Pittsburgh.
One of the major issues in the clinical management of kidney recipients with ABMR is the lack of early and reliable markers that surrogate long-term…
2018 American Transplant Congress
Comparison of Bortezomib in Addition to Rituximab Based Treatment of Acute Antibody Mediated Rejection in Kidney Transplantation
A. Mattiazzi,^1,2 J. Pagan,^1,2 A. Arunachalam,¹ I. De la Cruz Alcantara,¹ J. Revollo,² A. Centeno,² A. Valdes,^1,2 G. Guerra.^1,2
¹Nephrology & Hypertension, University of Miami, Miami, FL; ²Miami Transplant Institute, Jackson Memorial Hospital, Miami, FL.
Purpose:The optimal treatment strategy of acute antibody mediated rejection (AMR) in renal allograft recipients remains undefined. The aim of our study was to compare the…
2018 American Transplant Congress
Eluates from Fine-Needle Allograft Biopsy Increase Donor-Specific Antibody Identification in Antibody Mediated Rejection
A. Girnita,^1,2 E. Portwood,² P. Brailey,² M. Cuffy,¹ M. Cardi,¹ F. Paterno,¹ T. Diwan,¹ S. Shah,¹ A. Govil,¹ R. Alloway,¹ E. Woodle.¹
¹University of Cincinnati, Cincinnati; ²Hoxworth Blood Center, Cincinnati.
Aim. Antibody mediated rejection (AMR) represents a risk for graft loss, and the presence of circulating donor-specific antibody (cDSA) is a major criterion for AMR…
2018 American Transplant Congress
NK Cells in Allograft Kidney Biopsies during Rejection: Detection, Quantification, and Precise Localization Using Multiplex Immunofluorescence
M. Terada,¹ J. Duong Van Huyen,² F. Drieux,⁴ C. Legendre,³ P. Bruneval,¹ M. Rabant.²
¹Pathology Department, Georges Pompidou European Hospital, Paris, France; ²Pathology Department, Necker-Enfants Malades Hospital, Paris, France; ³Kidney Transplantation Department, Necker-Enfants Malades Hospital, Paris, France; ⁴Pathology Department, Centre Henri Becquerel, Rouen, France.
Introduction: Among the complex cellular interplay engaged in renal rejection, recent transcriptomic analysis of renal biopsies has detected NK cell transcripts in the setting of…
2018 American Transplant Congress
Clinical Response to Salvage Bortezomib Therapy for Antibody Mediated Rejection and Mixed Acute Rejection in a High Immunologic Risk Renal Transplant Population
A. Lichvar, J. Benken, E. Benedetti.
University of Illinois at Chicago, Chicago, IL.
Background: Proteasome inhibitor (PI) containing regimens treat antibody mediated rejection (AMR) and mixed acute rejection (MAR) due to elimination of donor specific antibody (DSA). Commonly,…
2018 American Transplant Congress
Subclass Distribution of DSA Analyzed by Mass Spectrometry Predicts the Risk of Humoral Rejection
V. Pernin,^1,2 N. Bec,³ C. Larroque,³ C. Duperray,² G. Mourad,¹ M. Lequintrec.^1,2
¹Department of Nephrology, Dialysis and Kidney Transplantation, CHU Lapeyronie, Montpellier, France; ²INSERM U1183 Institute for Regenerative Medicine & Biotherapy (IRMB), Montpellier, France; ³Institut de Recherche en Cancérologie de Montpellier (IRCM)- CRLC Val d'Aurelle - Paul Lamarque - INSERM U896, Montpellier, France.
Background :DSA occurrence after kidney transplant is a main risk factor for humoral rejection and graft loss, however graft outcomes after DSA detection is very…